Tianjin Pharmaceutical Da Ren Tang Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Tianjin Pharmaceutical Da Ren Tang Group hat ein Gesamteigenkapital von CN¥7.0B und eine Gesamtverschuldung von CN¥625.9M, wodurch sich der Verschuldungsgrad auf 8.9% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CN¥11.1B bzw. CN¥4.0B. Tianjin Pharmaceutical Da Ren Tang Group Das EBIT des Unternehmens beträgt CN¥816.1M, so dass der Zinsdeckungsgrad -2.7 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CN¥2.5B.

Wichtige Informationen

16.9%

Verhältnis von Schulden zu Eigenkapital

CN¥1.07b

Verschuldung

Zinsdeckungsgrad	-3.3x
Bargeld	CN¥3.51b
Eigenkapital	CN¥6.31b
Gesamtverbindlichkeiten	CN¥5.59b
Gesamtvermögen	CN¥11.90b

Jüngste Berichte zur Finanzlage

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Jul 05

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Mar 18

Recent updates

Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio

Jul 26

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Jul 05

Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

Apr 18

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Mar 18

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 600329Die kurzfristigen Aktiva des Unternehmens (CN¥7.4B) übersteigen seine kurzfristigen Passiva (CN¥3.7B).

Langfristige Verbindlichkeiten: 600329Die kurzfristigen Vermögenswerte des Unternehmens (CN¥7.4B) übersteigen seine langfristigen Verbindlichkeiten (CN¥351.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 600329 über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: 600329Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 3.8% auf 8.9% gestiegen.

Schuldendeckung: 600329Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (65.9%).

Zinsdeckung: 600329 mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.

Tianjin Pharmaceutical Da Ren Tang Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Recent updates

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.42 in 2Q 2023)

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) completed the acquisition of additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393).

Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report First Half, 2024 Results on Aug 15, 2024

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Final Dividend for the Year Ended December 31, 2023, Payable July 12, 2024

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Directorate and Committee Changes

First quarter 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.52 in 1Q 2023)

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Recommends Dividend

Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

New major risk - Dividend sustainability

Full year 2023 earnings: EPS and revenues miss analyst expectations

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, Annual General Meeting, May 15, 2024

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report Q1, 2024 Results on Apr 30, 2024

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Investor sentiment improves as stock rises 18%

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report Fiscal Year 2023 Results on Mar 30, 2024

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Board Changes

High number of new directors

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Cessation of Zhu Haifeng as an Independent and Non-Executive Director

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Resignation of Mr. Zhu Haifeng as an Independent Director of the Company, as Well as Chairman of Remuneration Committee, and A Member of Each of Audit Committee, the Nomination Committee, and Strategy Committee

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) agreed to acquire additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393) for CNY 87.8 million.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Appoints Ma Jian as Chief Financial Officer

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Provides Earnings Guidance for the Half Year Ended 30 June 2023

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report First Half, 2023 Results on Aug 15, 2023

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Executive Changes

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Approves Final Dividend for the Financial Period Ended 31 December 2022, Payable on or About 6 June 2023

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Cessation of Wong Gang as Independent and Non-Executive Director

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Resignation of Zhang as Director

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Appoints Wang Lei as General Manager

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Announces Final Dividend for the Financial Period Ended 31 December 2021, to Be Paid on or About 2 June 2022

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Appoints Zhang Yu as Chief Production Officer

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, Annual General Meeting, May 16, 2022

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Recommends to Declare Dividends for the Year Ended 31 December 2021

Tianjin Pharmacy Holdings Co., Ltd. completed the acquisition of 31.02% stake in Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (SGX:T14).

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Announces Cessation of Ni Zhenguo as Deputy General Manager

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited to Report Q3, 2020 Results on Oct 31, 2020

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Declares No Dividend Has for the Half Year Ended June 30, 2020

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited to Report First Half, 2020 Results on Aug 15, 2020

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen